The pharmacokinetics, pharmacodynamics and tolerability of PUR0200, a novel tiotropium formulation, in chronic obstructive pulmonary disease: PUR0200, a tiotropium formulation, in COPD

Aims

PUR0200 is a tiotropium bromide formulation engineered with the iSPERSE dry powder delivery technology. PUR0200 is being developed as a bioequivalent alternative to tiotropium bromide, delivered using Spiriva® HandiHaler® (HH). We investigated the bronchodilator effects, pharmacokinetics and safety of PUR0200 in patients with chronic obstructive pulmonary disease (COPD).

Methods

This was a randomized, placebo‐controlled, crossover study using different PUR0200 doses and the comparator tiotropium HH. In vitro aerodynamic particle size distribution (aPSD) characterization of PUR0200 and tiotropium HH are presented. The main endpoints included forced expiratory volume in 1 s (FEV₁) trough and (0–24 h) and pharmacokinetic parameters.

Results

The increased fine‐particle fraction of PUR0200 demonstrated by testing using the next‐generation impactor increased the proportion of drug available for lung deposition compared with the tiotropium HH. There was a numerical dose–response effect for PUR0200 on FEV₁, with 3 μg demonstrating a lower effect than higher doses. The placebo‐adjusted mean (95% confidence interval) increases from baseline at 24 h postdose were 150 ml (100–200), 210 ml (160–270) and 200 ml (140–250) for 3 μg, 6 μg and 9 μg doses of PUR0200, respectively. Tiotropium HH (18 μg) caused a mean 169 ml (standard deviation 157ml) improvement in trough FEV₁, which was not significantly different to the PUR0200 effects at any of the tested doses.

Conclusions

PUR0200 treatment caused bronchodilation in COPD patients that was similar in magnitude to that caused by tiotropium HH. This enabled a similar clinical effect on lung function to be achieved with PUR0200 using a lower metered dose of tiotropium compared with tiotropium HH.